Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oprozomib + Melphalan + Prednisone in NDMM
NCT02072863Phase 2Completed
- Sponsor
- Amgen
- Start
- Jan 2014
- Primary completion
- Jan 2015
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 3
01
Overview
A Phase 2 trial of oprozomib in multiple myeloma (MM), sponsored by Amgen. Started Jan 2014; status: completed.
02
Drugs
oprozomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02072863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02072863.